Apollomics, Inc.
APLMHealthcare|Biotechnology|US
$19.00
+2.02 (+11.90%)
Cash / Share
$7.78
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT04743505 Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) | Metastatic Non Small Cell Lung Cancer | P1P2 | Active | 27 | Open-label | APL-101, Osimertinib |
| NCT03175224 APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Solid Tumors, Advanced Cancer | P2 | Recruiting | 497 | Open-label | APL-101 Oral Capsules |
| NCT05054543 Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML | Relapsed/Refractory AML | P3 | Terminated | 140 | RCT, Double-blind | Uproleselan, Placebo |
| NCT03655613 APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC | Hepatocellular Carcinoma, Renal Cell Carcinoma | P1P2 | Terminated | 20 | Open-label | APL-501, APL-101, Nivolumab |
| NCT05367388 A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants | Bioequivalence | P1 | Unknown | 48 | RCT, Open-label | APL-101, PLB-1001 |
| NCT04839341 Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients | Relapsed/Refractory AML | P1 | Completed | 12 | Open-label | Uproleselan |
| NCT05055518 APL-102 Capsule in Patients With Advanced Solid Tumors | Advanced Solid Tumor | P1 | SUSPENDED | 30 | Open-label | APL-102 Capsules |
| NCT03053466 APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors | Solid Tumor, Microsatellite Instability | P1 | Completed | 30 | Open-label | APL-501 |